Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669942 · ClinicalTrials.gov registry record · Phase 1
Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT00669942 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 104 participants.
The verdict
NCT00669942, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as a single dose (intravenous infusion) in patients with active rheumatoid arthritis in combination with a stable dose of methotrexate. And to compare efficacy on the dose groups.
Interventions
- DRUG Placebo
- BIOLOGICAL AIN457
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669942
The ClinicalTrials.gov registry entry for NCT00669942 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00669942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669942 about?
NCT00669942 is a clinical study titled "Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients". Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as a single dose (intravenous infusion) in patients with active rheumatoid arthritis in combination with a stable dose of methotrexate. And to compare efficacy on the dose groups.
What is the current status of trial NCT00669942?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2005-12. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00669942?
The interventions under investigation include: Placebo (DRUG), AIN457 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00669942?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.